Cardlytics, Inc. reported impairment charges for the fourth quarter ended December 31, 2023. For the quarter, the company reported impairment of goodwill and intangible assets of $70,518,000 against $370,139,000 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.27 USD | -36.51% | -33.64% | +0.65% |
05-09 | Craig-Hallum Adjusts Cardlytics Price Target to $12 From $18, Maintains Buy Rating | MT |
05-09 | Needham Adjusts Price Target on Cardlytics to $12 From $17, Keeps Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.65% | 703M | |
+9.65% | 3,051B | |
+6.79% | 83.97B | |
+4.74% | 76.9B | |
-13.91% | 54B | |
+23.12% | 48.01B | |
-24.39% | 46.47B | |
+23.22% | 42.04B | |
+62.94% | 38.34B | |
-33.46% | 24.97B |
- Stock Market
- Equities
- CDLX Stock
- News Cardlytics, Inc.
- Cardlytics, Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023